In the beginning, there were two worlds in life sciences—separate, sovereign, and governed by different laws.

Operational technology (OT) ran the cleanroom, including bioreactors, programmable logic controllers (PLCs), and supervisory control and data acquisition (SCADA) systems engineered for precision and uninterrupted production.

Information technology (IT) ran the enterprise, with ERP, analytics, and supply chain platforms designed for connectivity and speed. Each excelled in its own orbit.

Today, their orbits overlap. Manufacturing execution systems (MES), quality platforms, and enterprise analytics now rely on continuous OT data to optimize yield, accelerate release, and synchronize supply chains, directly connecting production operations to IT platforms and cloud environments. IT/OT convergence drives modern biomanufacturing, but it also expands the attack surface and security complexity.¹ The global IT/OT convergence market is expected to exceed $1 trillion by 2027, underscoring how rapidly connected manufacturing is becoming the operational standard across life sciences and other regulated industries.²

The question now isn’t whether these worlds should connect. It’s how to protect production across connected manufacturing and IT operations, where uptime, compliance, and the patient access to therapies are directly linked.

Where IT/OT Convergence Creates Risk

When those worlds began to overlap, the assumptions that kept production safe stopped holding. OT systems were designed for stability: run the batch, protect the process, avoid interruption at all costs. IT systems were designed to move data, integrate systems, and enable enterprise-wide visibility. When those models intersect, protection gaps emerge—not because either side failed, but because neither was built for shared exposure across connected operations.

As production and IT systems operating as one, visibility and control gaps emerge across the converged technology stack:

• Systems – Legacy manufacturing platforms are now connected to enterprise and cloud networks without modern security protections
• Segmentation – Limited network segmentation between production and IT
• Access – Remote access pathways for vendors and support personnel extend into production operations
• Visibility – Incomplete visibility into operational system security posture across production systems
• Policy – Security policies designed for IT environments may not align with production uptime and validation requirements

Individually, each connection delivers value. Collectively, they create new, shared pathways between IT systems and production environments. A cyber incident that might interrupt enterprise workflows can propagate into manufacturing, halting active batches, compromising product integrity, and triggering GxP investigations that delay release and disrupt supply.

The Blind Spot Between the Plant Floor and the Business

The greatest risk in converged biomanufacturing environments is often not a single vulnerability, but the absence of unified visibility across production and IT systems.

IT teams may not fully see operational environments. OT teams may prioritize uptime over security changes that could affect validated systems. Enterprise security tools may not extend cleanly into production environments designed around different operational priorities.

This creates a governance blind spot.

Leadership may assume production systems are protected because IT systems are protected. But convergence introduces new pathways that span both IT and OT. Executive visibility must extend across the entire converged environment to ensure production systems remain secure, compliant, and operational, especially in life sciences, where production integrity directly affects regulatory approval and whether patients receive critical therapies on time.

What Leadership Must See Inside the Overlap

As OT and IT converge, governance must evolve with them. Executives need clear visibility into how connected production environments are operating, not just from an efficiency standpoint, but from a risk and compliance perspective.

Three areas define whether convergence strengthens production or introduces risk:

Availability – Protecting production without introducing downtime

Security must protect production without interrupting validated processes or destabilizing critical operations. Segmentation, access controls, and monitoring must be purpose-built for OT, where availability and batch continuity are nonnegotiable. Leaders need confidence that protection measures reduce risk without introducing operational disruption.

In biomanufacturing, security that interrupts production becomes operational risk itself.

Security and Compliance – Keeping manufacturing validated, audit-ready, and controlled

Convergence doesn’t change regulatory expectations. It increases the number of systems, integrations, and data flows that fall within GxP scope, along with the need to maintain continuous validation and compliance across them. Executives must be able to confirm that connected manufacturing environments remain validated, compliant, and inspection-ready at all times—not just at periodic review points.

Continuous visibility ensures compliance remains an operational condition, not something discovered during an inspection.

Visibility – Seeing risk early, before it reaches production

Not all risk appears as an incident. Most develops gradually through expanding integrations, unmanaged access pathways, configuration drift, and incomplete segmentation. Leadership needs visibility into how convergence is changing the production risk profile over time, allowing intervention before exposure affects batch integrity, operational continuity, or regulatory confidence.

In converged biomanufacturing environments, visibility determines whether exposure is prevented—or discovered too late, when it can delay batch release, trigger regulatory scrutiny, and disrupt patient access to therapies.

How NexusTek Helps Life Sciences Protect Connected Biomanufacturing

NexusTek helps life sciences organizations stabilize the point where IT and OT intersect, securing converged environments while protecting production uptime, product quality, and regulatory compliance.

By integrating security, infrastructure, and compliance visibility across the full production-to-enterprise ecosystem, NexusTek enables executive teams to:

• Maintain continuous visibility into manufacturing system security posture across converged IT and OT environments
• Control connectivity through network segmentation, identity governance, and managed access pathways
• Reduce cyber and compliance risk introduced by expanding system integration
• Detect and address risk before it affects production continuity, product integrity, or regulatory readiness
• Align production, security, and quality teams through shared visibility

This unified approach allows life sciences organizations to modernize manufacturing environments without compromising operational stability or regulatory confidence.

Innovation Only Works When Production Remains Protected

IT/OT convergence is transforming biomanufacturing. But connectivity alone doesn’t create resilience. Protection stabilizes the system once these worlds begin operating under the same conditions.

Executive visibility is what ensures connected production environments remain secure, compliant, and continuously operational—not just at the moment they connect, but as the new physics of biomanufacturing continues to evolve.

When worlds collide, stability isn’t automatic. It’s engineered.

Learn how NexusTek helps life sciences organizations protect biomanufacturing in the age of IT/OT convergence. https://www.nexustek.com/nexustek-life-sciences

1. IoT Analytics, OT cybersecurity: How IT/OT convergence and AI are changing security architectures, January 2026
2. Jeff Winter Insights, IT/OT convergence—how big is it?, April 2025